@article{2024-01-30,
author = {, , , , , , , , , , },
title = {},
year = {2023},
doi = {10.2174/0113816128262498231122072050},
publisher = {NP «NEICON»},
abstract = {Introduction: Renal cancer ranks 10th in the mortality structure of the Russian Federation. The introduction of checkpoint inhibitors has changed the paradigm of treatment of patients with malignant neoplasms. Methods: Data from clinical trials have shown good progression-free median and median overall survival. Each cancer center has been accumulating its own experience in treating patients with renal cell cancer by app-lying modern target drugs and immunotherapy. Results: In routine clinical practice, oncologists do not get the results that have been demonstrated in clinical trials when evaluating the effectiveness of the therapy. Conclusion: In this single-center clinical study, we discuss the results of using nivolumab as mono-therapy and the combination of nivolumab with ipilimumab in metastatic renal parenchyma cancer patients. © 2023 Bentham Science Publishers.},
URL = {https://repo.bashgmu.ru/publication/2869},
eprint = {https://repo.bashgmu.ru/files/3045},
}